Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 428,400 shares, a growth of 152.1% from the September 15th total of 169,900 shares. Currently, 10.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 217,700 shares, the short-interest ratio is currently 2.0 days. Based on an average daily trading volume, of 217,700 shares, the short-interest ratio is currently 2.0 days. Currently, 10.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Qube Research & Technologies Ltd bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $28,000. AQR Capital Management LLC increased its holdings in Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after purchasing an additional 44,275 shares during the period. Invesco Ltd. increased its holdings in Verrica Pharmaceuticals by 64.8% during the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after purchasing an additional 29,256 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Verrica Pharmaceuticals by 127.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company’s stock worth $44,000 after purchasing an additional 55,852 shares during the period. Finally, Kovitz Investment Group Partners LLC purchased a new position in Verrica Pharmaceuticals during the 1st quarter worth $45,000. 42.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Verrica Pharmaceuticals has an average rating of “Hold” and a consensus price target of $60.00.

Verrica Pharmaceuticals Price Performance

NASDAQ:VRCA opened at $4.15 on Friday. The firm has a market capitalization of $39.22 million, a price-to-earnings ratio of -0.50 and a beta of 1.71. Verrica Pharmaceuticals has a 1 year low of $3.82 and a 1 year high of $17.38. The business has a 50 day simple moving average of $4.99 and a 200-day simple moving average of $5.60.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.72. The business had revenue of $12.70 million for the quarter, compared to the consensus estimate of $4.37 million. As a group, analysts expect that Verrica Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.